2009
Archer Daniels Midland, Lawrence
The KBA awarded $1.2 million over three years for bioenergy research at the University of Kansas Center for Environmentally Beneficial Catalysis as a match to $1.2 million being invested by Archer Daniels Midland Company, which operates five processing plants, a technical center, and sales and distribution offices throughout Kansas. Research will focus on converting multiple feedstocks, including biomass, into a wide platform of fuels and chemicals to replace or improve upon petroleum-based products. The university will provide in-kind support valued at more than $334,000.
(5/19/2009).
Expected or Realized Outcomes: Research funding of $1.2 million plus this projection could lead to new technologies that can be integrated into one or more of ADM’s five processing plants in the state and new feedstocks that can be grown, harvested and processed in Kansas.
Center of Innovation for Biomaterials in Orthopaedic Research, Wichita, Kansas
The KBA awarded $4 million for the Center of Innovation for Biomaterials
in Orthopaedic Research (CIBOR) to create medical instruments, medical devices, and composite implants that will improve the practice of orthopedic medicine. The center will focus on commercial viability, conducting research requested by industry to meet market needs and capitalizing on the concentration of composites expertise found in Wichita due to the state’s longstanding aviation industry leadership. Partnering to form this center are Wichita State University, the National Institute of Aviation Research, the Wichita Composites Advisory Board, Kansas State University, Pittsburg State University, and Via Christi Health.
(5/19/2009).
Expected or Realized Outcomes: A biomaterials sector that will bring together diverse institutions, universities, companies and individuals in the state with proven and synergistic expertise to contribute $100 million to the Kansas economy over 10 years. The center will create medical instruments, medical devices, and composite implants that will improve the practice of orthopaedic medicine. CIBOR is expected to increase employment in Kansas by 2,000 over 10 years.
Collaborative Cancer Research Initiative, Lawrence, Kansas
The KBA awarded $500,000 to the Collaborative Cancer Research Initiative (CCRI) for collaborative studies by the University of Kansas Cancer Center and Scripps Research Institute. The research is intended to reduce the unwanted toxicity often associated with chemotherapy and improve the treatment of breast and prostate cancers.
(5/19/2009).
Expected or Realized Outcomes: Expand existing cancer research in Kansas and contribute to NCI designation in 2011.
Collaborative Cancer Research Initiative, Wichita, Kansas
The KBA awarded a second $500,000 CCRI investment to initiate Phase I clinical trials in the Wichita area through a partnership of the University of Kansas Cancer Center, Cancer Center of Kansas, Midwest Cancer Alliance and Via Christi Regional Medical Center. Phase I trials will complement the successful Phase II and III programs in Wichita and strengthen rural and regional treatment options.
(5/19/2009).
Expected or Realized Outcomes: Phase I trials will complement the successful Phase II and III programs in Wichita and strengthen rural and regional treatment options.
CritiTech and SCF Technologies , Lawrence, Kansas
The KBA awarded $50,000 to CritiTech and SCF Technologies of Lawrence to further develop a novel approach to converting drugs into dry, sterile powder form. The process is expected to significantly reduce costs in drug manufacturing, while easing the process of administering drugs for both physicians and patients.
(5/19/2009).
Expected or Realized Outcomes: The investment is a partial match to a $100,000 grant from the National Cancer Institute.
CyDex Pharmaceuticals, Inc., Lenexa, Kansas
The KBA awarded $195,000 to Lenexa-based CyDex Pharmaceuticals to commercialize re-formulated drugs that address limitations of existing therapies. A focus will be improving a cancer drug for patients with multiple myeloma.
(5/19/2009).
Expected or Realized Outcomes: Private funding support to the University of Kansas which builds research excellence at a Kansas university and supports the Kansas University Cancer Center. In addition, furthers the development of CyDex’s cancer drugs which will generate future tax revenue in Kansas.
Kansas Innovation Center for Advanced Plant Design , Manhattan, Kansas
The KBA awarded $4 million over two years to the Kansas Innovation Center for Advanced Plant Design (KICAPD) to develop advanced technologies for gene discovery, trait validation and crop improvement in order to deliver new products and production platforms. The global research team associated with the center will focus on emerging commercial opportunities for wheat and sorghum, crops in which Kansas has world-renowned leadership and expertise. The center is a public and private collaboration of Kansas Wheat, Kansas State University, the University of Kansas, and many private investors.
(5/19/2009).
Expected or Realized Outcomes: Kansas could lead the innovative development of wheat and sorghum, particularly in the drought resistant and high-yielding areas. The center projects creating 90 jobs and at least nine commercial start-ups within five years. Within 10 years, the center projects the creation of 36 patents, 20 commercial start-ups and 285 jobs.
NanoScale, Manhattan, Kansas
The KBA awarded $50,000 in matching funds to Manhattan-based NanoScale to expedite the testing of nanoparticles for diagnostic and therapeutic uses in fighting cancer. These “stealth” particles are expected to allow earlier disease detection and to improve the ability of drugs to hit their intended targets with fewer side effects.
(5/19/2009).
Expected or Realized Outcomes: $150,000 in federal funding and completion of this work will build the foundation for the target scope of work for an NIH SBIR II grant application and provide the proof of concept required to move this application into the commercial marketplace.
University of Kansas Cancer Center, Kansas
A $600,000 project budget was committed for the KBA to support the University of Kansas Cancer Center’s efforts to bring cutting-edge cancer treatments closer to home for millions of Kansans through National Cancer Institute designation.
(5/19/2009).
Expected or Realized Outcomes: National Cancer Institute designation for the University of Kansas Cancer Center.
Lawrence-Douglas County Bioscience Authority wet lab incubator, Lawrence, Kansas
The KBA awarded $3.25 million over three years in matching funds to the Lawrence-Douglas County Bioscience Authority for a wet lab incubator at the University of Kansas. The incubator will facilitate the growth of the bioscience industry in Douglas County and supplement other existing or proposed incubators in the Kansas City metro region. The facility’s location will allow it to attract customers who seek close proximity to KU, and the community and university will invest $4 million in the project.
(3/10/2009).
Expected or Realized Outcomes: Capital expenditures of $6.5 million and assistance for start-up companies leading to employment growth.
High Throughput Screening Compound Management System, Kansas City, Kan.
The KBA awarded $500,000 to the University of Kansas for an automated compounds management system at the University of Kansas High Throughput Screening Laboratory. This automated compound management system will play a highly significant role in catalyzing collaboration between the University of Kansas and Kansas State University. Specifically, it will allow for joint cancer research to be conducted where very large chemical compounds libraries can be rapidly screened so binding targets can be quickly identified and made available to the commercial drug discovery process.
(3/9/2009).
Expected or Realized Outcomes: A national screening center for disease-focused foundations and societies and increased funding from the NIH and industry-sponsored applied research.
Kansas Bioenergy and Biorefining Center of Innovation, Kansas
The KBA awarded $4.1 million to create the Kansas Bioenergy and Biorefining Center of Innovation, uniting key industry players with the world-class research and development efforts at the University of Kansas and Kansas State University. The center of innovation will use commercial biorefining to develop alternative fuels and chemicals; commercialize efficient biomass resources for cost-effective quality power; and improve carbon capture.
(3/9/2009).
Expected or Realized Outcomes: Three biorefineries and $600 million in sales of cellulosic ethanol over five years; addition of 1,800 direct jobs, 3,600 indirect jobs; direct revenue of $3.6 billion, and extra income of $30,000 per harvest per farm.
Kansas Bioscience Innovation Center in Drug Delivery, Kansas City, Kan.
The KBA awarded $5 million to the University of Kansas Medical Center in Kansas City, Kan. for the Kansas Bioscience Innovation Center in Drug Delivery. The Kansas Bioscience Innovation Center in Drug Delivery is a collaboration of industry, the University of Kansas, and Kansas State University that will transform existing outstanding academic drug delivery capabilities into an integrated, high performance, world-class drug delivery organization.
(3/9/2009).
Expected or Realized Outcomes: $900 million in economic impact over 10 years; 300 jobs; and hundreds of inventions, patents, and start-up companies.
Targeting Novel Wnt-PTEN Pathways in Cancer Stem Cell, Kansas City, Kan.
The KBA awarded $250,000 to a team from the University of Kansas for research to develop drug candidates that target the cells that start tumors and support tumor growth.
(3/9/2009).
Expected or Realized Outcomes: Increased cancer research in Kansas and expanded cancer research capabilities.
University of Kansas Cancer Center (Wahl/Hixon Research Complex), Kansas City, Kan.
The KBA awarded $26.4 million for state-of-the-art cancer research space at the University of Kansas Medical Center (KUCC) in Kansas City, Kan. to advance its cancer research program for National Cancer Institute (NCI) designation and to recruit cancer-related eminent, rising star, and emerging scholars. KUCC has identified 170,000 gross square feet in the Wahl/Hixon Research Complex to meet the near-term, state-of-the-art space needs for basic and translational cancer research. The total estimated renovation cost is $50 million, of which $34 million is for design and construction and $16 million is for equipment. The KBA investment will support 10 years of bond payments for construction costs.
(3/9/2009).
Expected or Realized Outcomes: Over the 10 years of the KBA’s financing, in constant dollars, these 37 Principal Investigators (PIs) will generate nearly $151 million, of which $113 million is direct and $38 million is indirect. In addition the 37 PIs will need 204 research staff.
Edenspace Systems, Manhattan, Kansas
The KBA awarded $360,000 to Manhattan-based Edenspace Systems as a partial match to a $750,000 grant from the U.S. Department of Energy and a $350,000 grant from the U.S. Department of Agriculture. The funding will support the further development of technology to lower processing costs and increase yields of biofuels from sorghum, corn, and switchgrass.
(1/27/2009).
Expected or Realized Outcomes: $1.1 million in federal research funding.
ICM, Colwich, Kansas
The KBA awarded $500,000 to ICM to support the testing of a biomass gasification system that converts waste to synthetic fuel gas for power generation in industrial and commercial settings. The technology is intended to serve small communities that need to safely dispose of waste while generating reliable power for the electric grid. The company will invest an additional $1.7 million in the project and receive an in-kind land-use contribution from Harvey County.
(1/27/2009).
Expected or Realized Outcomes: $1.7 million in capital investment and operations.
KBA Venture Accelerator, Olathe, Kansas
The KBA has committed $19 million for the KBA incubator building at the Kansas Bioscience Park.
(1/27/2009).
Expected or Realized Outcomes: The project will benefit the KBA’s efforts to foster the formation and growth of bioscience companies.
VasoGenix Pharmaceuticals, Lenexa, Kansas
The KBA awarded $400,000 to VasoGenix Pharmaceuticals to support the ongoing development of an IV and controlled-release drug treatment for acute decompensated heart failure, a disease that affects 5 million people and 550,000 new patients annually. The company is raising capital for the filing of an investigational new drug application with the U.S. Food and Drug Administration.
(1/27/2009).
Expected or Realized Outcomes: $400,000 in private investment capital and progress in the FDA IND application process.
ANOxA CORP, Kansas
The KBA awarded $300,000 to ANOxA CORP, an animal-health biotechnology company, for the commercialization of a new drug to treat a common equine disorder should it move its headquarters to Kansas. The company is expected to hire seven employees upon relocation.
(10/28/2008).
Expected or Realized Outcomes: Seven new employees, relocation to Kansas, and $6 million in equity financing.
ICM, Colwich, Kansas
The KBA awarded $1 million to Colwich-based ICM for a collaborative bioenergy research project to bring cellulosic ethanol solutions to the marketplace using non-food sources such as switchgrass, corn fiber, and sorghum. ICM will work with Edenspace Systems, Diamond Ag, and Kansas State University following the U.S. Department of Energy’s recent selection of ICM as one of four small-scale biorefinery companies to lead biomass-to-ethanol research efforts using innovative conversion technologies.
(10/28/2008).
Expected or Realized Outcomes: $3 million in research funding.
Kansas State University, Manhattan, Kansas
The KBA awarded $300,000 to Kansas State University to create a county-level inventory of biomass resources such as agricultural crop residues; grain and oilseed crops; and herbaceous energy crops. As part of the KBA’s development of a strategic plan to advance the state’s national bioenergy leadership, this data will highlight opportunities for the state as its bioenergy sector expands to help the country meet the National Renewable Fuels Standard, which federally mandates a significant increase in non-corn based biofuel use.
(10/28/2008).
Expected or Realized Outcomes: A comprehensive inventory of biomass resources in the state to support bioenergy industry growth.
NOWA Technology, Prairie Village, Kansas
The KBA awarded a $1.5 million loan to NOWA Technology to commercialize its patent-pending technology that chemically extracts marketable products such as fuel oil and mineral salts from municipal wastewater and eliminates the need to incinerate or landfill sludge. This proprietary process reduces wastewater treatment costs while providing significant environmental benefits.
(10/28/2008).
Expected or Realized Outcomes: $2.5 million in private investment capital.
Pinnacle Technology, Lawrence, Kansas
The KBA awarded $375,000 to Pinnacle Technology for the commercialization of a wireless neurochemical biosensor for laboratory research that supports the pre-clinical development of new pharmaceuticals. The investment will partially match a Phase II Small Business Innovation Research grant from the National Institutes of Health.
(10/28/2008).
Expected or Realized Outcomes: $840,000 in research funding.
University of Kansas Cancer Center, Kansas City, Kansas
The KBA awarded $750,000 to the University of Kansas Cancer Center to hire three researchers to support the work of center director Dr. Roy Jensen as KU seeks National Cancer Institute designation as a comprehensive cancer center.
(10/28/2008).
Expected or Realized Outcomes: $300,000 per year in research funding.
Via Christi Medical Center, Wichita, Kansas
The KBA awarded $327,500 to Via Christi Medical Center to secure a researcher to work with KBA eminent scholar Dr. Paul Wooley as he studies the biocompatibility of composite implants leading to orthopedic surgery applications such as prosthetic joints.
(10/28/2008).
Expected or Realized Outcomes: Approximately $750,000 in research funding.
Wichita Center for Graduate Medical Education, Wichita, Kansas
The KBA awarded $5.88 million to the Wichita Center for Graduate Medical Education for a research program that will lead to the creation of three new research centers. These centers are intended to improve health care delivery and patient outcomes; potentially lead to new drugs, medical products, and intellectual property; and serve as the basis for sustained accreditation of the 14 medical residency programs in Wichita.
(10/28/2008).
Expected or Realized Outcomes: Three self-sustaining research centers.
KC BioMediX, Shawnee, Kansas
The KBA made an equity investment of $400,000 in KC BioMediX to commercialize technologies developed at the University of Kansas for the care of infants born prematurely. The company’s FDA-approved device, the NTrainer System, uses state-of-the-art hardware and software to treat preemies who have difficulty feeding orally so they can quickly gain strength and grow. This award follows a $150,000 KBA investment last fall and is part of a $4 million round of company financing.
(7/15/2008).
Expected or Realized Outcomes: $3.6 million in private investment capital.
MGP Ingredients, Atchison, Kansas
The KBA awarded $500,000 for the development and further commercialization of biobased, biodegradable resins to economically replace plastic. The biobased resin can be used for products such as disposable cutlery, DVD cases, and bottle caps — and is biodegradable.
(7/15/2008).
Expected or Realized Outcomes: 54 new jobs and $9.9 million in capital investment.
VasoGenix Pharmaceuticals, Lenexa, Kansas
The KBA awarded a $200,000 convertible note to support the development of an IV and controlled-release drug treatment for acute decompensated heart failure, a disease that affects 5 million people and 550,000 new patients annually. The company is completing pre-clinical studies of its treatment that uses a molecule with a history of safe use in humans and which aims to improve human health while reducing re-hospitalization costs by $6 billion per year.
(7/15/2008).
Expected or Realized Outcomes: $200,000 in private investment.